QPPV.COM

What Is an EMA Referral? Why Referrals Are Started and How the EU Referral System Works

A practical and regulatory guide to EMA referral procedures, distinguishing safety signals from formal referrals and explaining the roles of PRAC, CHMP, CMDh and the European Commission.

Audio Lesson 23 min

What Is an EMA Referral? Why Referrals Are Started and How the EU Referral System Works

Overall structure

This article explains the EU referral system as a connected regulatory framework rather than treating individual referral procedures as isolated definitions.

  1. What an EMA referral is
  2. Why the EU needs referral procedures
  3. Referral versus safety signal
  4. When a concern becomes a formal referral
  5. The principal referral pathways
  6. Article 20 procedures
  7. Article 31 referrals
  8. Article 107i urgent Union procedures
  9. Article 30 harmonisation referrals
  10. Comparing the principal pathways
  11. Referral scope and affected products
  12. Initiation and notification
  13. Scientific assessment and committee roles
  14. PRAC, CHMP and CMDh interfaces
  15. Evidence and regulatory questions
  16. Recommendations, opinions and decisions
  17. Re-examination
  18. Implementation and product information
  19. Pharmacovigilance and QPPV implications
  20. Reading and auditing an individual referral
  21. Common regulatory misconceptions
  22. Practical referral checklist
  23. References and regulatory note

1. What Is an EMA Referral?

An EMA referral is a formal European regulatory procedure used to resolve a defined scientific or regulatory question concerning one or more medicinal products and, where applicable, establish a common position across the European Union.

The question may concern safety, efficacy, quality, conditions of use, divergent national decisions or another matter for which EU legislation provides a referral mechanism.

The word referral should not be interpreted as meaning that a medicine has already been found unsafe, ineffective or non-compliant.

The referral is the procedure through which the defined question is assessed.

The legal basis determines:

The first question when reviewing a referral should therefore be:

What exact regulatory question has been referred, under which legal basis, and for which products?

That question prevents the common mistake of treating all EMA referrals as if they were the same procedure.

2. Why Does the EU Need Referral Procedures?

Medicinal products in the EU can be authorised through different regulatory routes.

Some are centrally authorised. Others are authorised nationally or through mutual-recognition and decentralised procedures.

This regulatory diversity creates circumstances in which a scientific or regulatory issue may require coordinated Union-level assessment.

For example, the same active substance may be authorised in several Member States while different national decisions have been adopted about its conditions of use.

A safety concern can also affect patients in multiple Member States even when the initial evidence is detected nationally.

Without a Union mechanism, the result could be materially inconsistent:

Referral procedures provide a defined legal route for bringing such questions into an EU-level assessment.

The purpose is not merely administrative uniformity. In safety-related procedures, harmonised regulatory action can directly affect prescribing, dispensing and patient protection.

3. Referral Versus Safety Signal

A safety signal and an EMA referral are related concepts, but they are not interchangeable.

A safety signal is information suggesting a new or changed causal association between a medicinal product and an event that warrants further investigation.

Signal management is primarily a pharmacovigilance activity and can involve:

A referral is a formal regulatory procedure established under EU legislation.

A signal may contribute to the evidence that ultimately leads to a referral, but many signals are managed without becoming referrals.

Conversely, not every referral begins with a conventional pharmacovigilance signal. Article 30, for example, addresses qualifying divergence between national regulatory decisions.

The conceptual sequence can therefore be:

Safety information or other regulatory concern
                    ↓
             Scientific evaluation
                    ↓
             Regulatory question
                    ↓
        Referral, where legally applicable
                    ↓
             EU-level assessment
                    ↓
              Regulatory outcome

The referral is therefore a regulatory process, not simply a more serious form of signal.

4. When Does a Concern Become a Referral?

There is no single universal threshold at which every concern becomes an EU referral.

The applicable legal procedure determines when a referral is available and what conditions must be satisfied.

A concern may initially be managed through ordinary pharmacovigilance or regulatory processes, such as:

A referral becomes relevant when the circumstances satisfy the statutory conditions of a particular EU procedure.

This distinction is important because the choice of legal pathway determines the procedural architecture.

Among other things, it affects:

The correct procedure should therefore be established from the legal trigger, not from the seriousness of the issue alone.

5. The Principal Referral Pathways

For human medicines, four referral pathways are particularly important when explaining the EU system:

Pathway Principal regulatory context Core scientific focus
Article 20 Centrally authorised medicines Safety, quality or efficacy depending on procedure
Article 30 Divergent national decisions Harmonisation and scientific/regulatory assessment
Article 31 Union-interest referral Pharmacovigilance or other data, depending on pathway
Article 107i Urgent Union safety procedure Urgent pharmacovigilance action

These categories are teaching aids, not substitutes for reading the legislation.

The exact scope of a referral must always be confirmed from the formal notification and procedure-specific documents.

In particular, Article 31 has distinct pharmacovigilance and non-pharmacovigilance pathways. The committee and evidence pathway therefore depend on the nature of the referral.

6. Article 20 Procedures

Article 20 of Regulation (EC) No 726/2004 provides a referral mechanism concerning centrally authorised medicinal products.

Depending on the issue, the procedure can involve quality, safety or efficacy considerations.

For pharmacovigilance-related Article 20 procedures, PRAC has a central role in the scientific safety assessment.

The pathway is therefore closely associated with centrally authorised products, but the term Article 20 referral should not automatically be treated as synonymous with a pharmacovigilance procedure.

The actual regulatory question and applicable procedural documents determine the assessment.

For regulatory teams, the first classification questions are:

  1. Is the product centrally authorised?
  2. Is the referral under Article 20?
  3. Is the issue pharmacovigilance-related?
  4. Which committee and subsequent decision route apply?

Those questions establish the procedural starting point.

7. Article 31 Referrals

Article 31 of Directive 2001/83/EC provides an important Union referral mechanism for medicinal products within its scope.

Article 31 includes a pharmacovigilance pathway where the interests of the Union are involved and the procedure is initiated as a result of evaluation of pharmacovigilance data concerning authorised medicinal products, subject to the statutory conditions and relationship with Article 107i.

Article 31 also provides a non-pharmacovigilance pathway for concerns arising from data other than pharmacovigilance data.

That distinction is essential.

A pharmacovigilance Article 31 referral is assessed through the PRAC-led safety pathway.

A non-pharmacovigilance Article 31 referral can concern matters such as quality or efficacy and follows the applicable CHMP pathway.

Therefore, saying simply "Article 31 referral" is often insufficient for a regulatory record.

The record should specify whether the procedure is:

8. Article 107i: The Urgent Union Procedure

Article 107i of Directive 2001/83/EC provides a procedure for urgent Union-level action in relation to safety concerns.

Its defining characteristic is urgency.

The procedure becomes relevant when a Member State or the European Commission considers that urgent action is necessary because of a safety issue and the statutory conditions are met.

Depending on the circumstances, the regulatory question can involve measures such as:

PRAC performs the pharmacovigilance assessment within the Article 107i framework.

The resulting recommendation then proceeds through the applicable regulatory route.

Article 107i should therefore not be treated as merely another name for a routine safety referral.

9. Article 30: Harmonisation of Divergent National Decisions

Article 30 addresses a different regulatory problem.

It provides a mechanism for dealing with qualifying divergent decisions adopted by Member States concerning the authorisation of nationally authorised medicinal products.

The divergence can concern matters such as:

The purpose is to achieve a harmonised Union position through the applicable scientific and regulatory procedure.

Article 30 is therefore not principally a pharmacovigilance referral mechanism.

A product can enter an Article 30 referral because Member States have reached different regulatory conclusions even when the immediate trigger is not a newly detected safety signal.

This distinction is particularly important when interpreting referral statistics or comparing Article 30 with Articles 31 and 107i.

10. Comparing the Main Pathways

A useful high-level comparison is:

Feature Article 20 Article 30 Article 31 PV Article 31 non-PV Article 107i
Main context Centrally authorised medicines Divergent national decisions Union-interest safety referral Union-interest non-PV referral Urgent safety issue
Typical scientific lead PRAC or CHMP depending on issue CHMP PRAC CHMP PRAC
Core concern Safety, quality or efficacy Harmonisation Pharmacovigilance Quality/efficacy or other non-PV data Urgent pharmacovigilance
Primary legislation Regulation 726/2004 Directive 2001/83/EC Directive 2001/83/EC Directive 2001/83/EC Directive 2001/83/EC
Urgency defining feature No No No No Yes

The table is deliberately simplified.

A live regulatory assessment should verify the exact legal basis, product scope, committee pathway and decision mechanism from the current legislation and procedure-specific documents.

The most important lesson is that the procedure name is not enough. The legal basis, trigger, product authorisation route and referral question must all be understood together.

11. Defining the Referral Scope

The first substantive task in reviewing a referral is to determine exactly what is within scope.

The scope may be defined by:

The formal referral notification is the primary starting point for this determination.

A company should not assume that every aspect of an affected product is being reassessed merely because the product appears in the referral.

The questions referred to the committee define the scientific assessment boundary.

12. Why Scope Control Matters

Scope control prevents two opposite errors.

The first is under-scoping: failing to assess a product, presentation, population or indication that is actually covered.

The second is over-scoping: treating the procedure as a complete reassessment of matters that were never referred.

A useful internal scope matrix is:

Dimension Question
Product Which medicinal products are included?
Substance Which active substance or substances?
Authorisation Which authorisations are affected?
Population Which patients are relevant?
Indication Which therapeutic uses?
Safety issue What specific concern?
Regulatory question What must the committee decide?

This matrix should be reconciled with the formal procedure documents.

13. The Referral Question

The referral question is the regulatory question that the scientific committee has been asked to answer.

It can concern matters such as:

The exact wording matters because it determines what evidence is relevant.

A scientific review should therefore begin with the question, not with a general review of everything known about the medicine.

The legal basis determines the procedural architecture.

For example, the same safety concern can have different procedural consequences depending on whether the products are centrally authorised, nationally authorised, or whether urgent action is required.

The reviewer should establish:

  1. the cited legal provision;
  2. the authorisation route;
  3. the initiating authority;
  4. the committee responsible for assessment;
  5. the regulatory instrument expected at the end of the procedure.

This prevents the common error of applying Article 20, Article 31 and Article 107i concepts interchangeably.

15. Centrally Authorised Products

Centrally authorised medicinal products follow the Union authorisation system established under Regulation (EC) No 726/2004.

For safety-related questions, Article 20 can provide a specific referral pathway for centrally authorised products.

PRAC performs the pharmacovigilance assessment where the procedure concerns pharmacovigilance data.

The resulting recommendation enters the applicable Union decision-making process.

The practical lesson is simple: when opening a referral, establish whether the product is centrally authorised before assuming which committee or legal route applies.

16. Nationally Authorised Products

Nationally authorised products can be subject to several Union-level procedures depending on the circumstances.

Article 31 is particularly important where the interests of the Union are involved and the procedure is initiated following evaluation of pharmacovigilance data.

The products may be authorised in one or several Member States.

The authorisation history therefore becomes an important part of the regulatory assessment.

A national authorisation does not mean that a safety concern must remain a national matter.

17. Mutual Recognition and Decentralised Procedures

Medicines authorised through MRP or DCP can have a particularly complex regulatory history because several national authorities may be involved.

The relevant history can include:

When reviewing a referral, the original MRP or DCP history should be separated from the later referral process.

The earlier procedure explains the authorisation history; the referral establishes the current regulatory question.

18. The Role of the Member State Competent Authority

National competent authorities remain important participants in the EU referral system.

They may identify emerging regulatory concerns, initiate procedures where the law permits, contribute scientific expertise and implement final regulatory outcomes.

A referral does not mean that national regulators disappear from the process.

Instead, the procedure creates a defined mechanism for resolving an issue at Union level while retaining the operational role of national authorities where the applicable authorisation route requires it.

19. The Role of the European Commission

The European Commission has several possible roles depending on the referral pathway.

It can initiate certain procedures, participate in the regulatory framework and adopt legally operative decisions where the applicable legislation provides for a Commission decision.

This is particularly important when distinguishing a scientific recommendation from a binding regulatory outcome.

The final legal effect must be established from the applicable instrument rather than inferred from a committee meeting summary.

20. The Role of the MAH

The marketing authorisation holder is responsible for supplying relevant information and responding to regulatory questions within the applicable procedure.

Depending on the referral, this can involve:

The MAH should establish a controlled cross-functional process for preparing responses.

21. The QPPV and Pharmacovigilance Function

For safety-related referrals, the pharmacovigilance function has an important role in ensuring that the regulatory response is consistent with the company's safety database and pharmacovigilance system.

The QPPV and relevant safety experts should be able to establish:

This historical reconstruction is often essential when responding to detailed regulatory questions.

22. Regulatory, Medical and Clinical Integration

A referral response should rarely be treated as the responsibility of a single department.

Depending on the issue, appropriate contributors can include:

The final submission should nevertheless have a single controlled regulatory narrative.

Different functions should not submit internally inconsistent interpretations of the same evidence.

23. The Evidence Base

A referral assessment can draw on multiple evidence sources.

These can include:

The evidentiary value of each source depends on the specific question.

The existence of a large number of reports does not automatically establish causality, just as the absence of reports does not automatically establish absence of risk.

24. Individual Case Safety Reports

Individual case safety reports can be important evidence in a safety referral.

Assessment may consider:

Case-level evidence should normally be integrated with aggregate evidence rather than interpreted in isolation.

25. Aggregate Evidence

Aggregate analyses help determine whether a pattern is consistent across patients and data sources.

Depending on the issue, this can include:

The analytical method should be appropriate to the question and underlying data quality.

A statistical association should not automatically be presented as proof of causality.

26. Causality Assessment

Causality is often a central scientific question in a safety referral.

The assessment should distinguish:

  1. temporal association;
  2. statistical association;
  3. biological plausibility;
  4. consistency across evidence sources;
  5. alternative explanations;
  6. strength and specificity of the association.

No single criterion necessarily determines the conclusion.

The final assessment should integrate the available evidence.

27. Exposure and Denominator Data

The interpretation of adverse-event reporting depends partly on exposure.

Useful information can include:

Without an appropriate denominator, raw report counts can be misleading.

For example, a product with substantially higher patient exposure may generate more reports even if the underlying risk is not higher.

28. Subgroup Analysis

Safety risks may not be distributed uniformly across the treated population.

Potentially relevant subgroups include:

A referral question should therefore be assessed at the level of the population actually affected by the concern.

29. Benefit-Risk Assessment

The existence of a safety risk does not automatically mean that a medicine should be withdrawn.

Regulatory assessment generally considers the relationship between:

The appropriate regulatory response depends on the integrated benefit-risk assessment and the applicable legal standard.

30. From Scientific Finding to Regulatory Action

A referral becomes operationally important when the scientific assessment is translated into a regulatory conclusion.

The conceptual chain is:

Evidence
   ↓
Scientific assessment
   ↓
Benefit-risk conclusion
   ↓
Regulatory recommendation / opinion
   ↓
Legal decision
   ↓
Implementation

Keeping these stages separate is essential.

A scientific finding does not by itself establish the final legal obligation, and a regulatory decision should be traceable back to the evidence and reasoning supporting it.

31. Initiation of a Referral

A formal referral begins through the legal mechanism applicable to the specific situation.

The initiating document should establish the issue sufficiently for the receiving committee and stakeholders to understand:

The referral notification is therefore more than an announcement. It establishes the procedural starting point and helps define the scope of the assessment.

32. Referral Timetables

Each referral follows a procedure-specific timetable.

Important milestones can include:

The current procedure-specific timetable should always take precedence over generic timelines described in educational material.

33. Appointment of Rapporteurs

The responsible committee appoints scientific assessors according to the applicable procedure.

Rapporteurs lead the assessment and prepare material for committee consideration.

Their role can include:

A rapporteur's assessment is not itself the final regulatory decision.

The distinction between assessor analysis and committee conclusion should remain explicit throughout the regulatory record.

34. PRAC in Pharmacovigilance Referrals

For procedures involving pharmacovigilance data where PRAC is the responsible scientific committee, PRAC performs the detailed safety assessment.

PRAC can consider:

The resulting recommendation then follows the legal pathway applicable to the referral.

PRAC should therefore be understood as a scientific pharmacovigilance committee within the Union system, not as the body that automatically makes every final legal decision.

35. CHMP in Referral Procedures

CHMP is the principal scientific committee for medicinal products for human use in the Union authorisation system.

Depending on the referral mechanism, CHMP may consider the scientific assessment directly or receive a recommendation from PRAC.

CHMP's role can include assessment of:

The precise role depends on the legal pathway.

36. CMDh in Nationally Authorised Medicine Procedures

CMDh coordinates Member State positions concerning nationally authorised medicines, particularly in the context of mutual-recognition and decentralised procedures.

Its role should not be confused with PRAC or CHMP.

CMDh may be relevant to the implementation or coordination of certain procedures involving nationally authorised products, while PRAC and CHMP have defined scientific roles under the applicable referral mechanisms.

The committee named in the formal procedure should always be treated as the authoritative indicator of procedural responsibility.

37. Submission of the MAH Evidence

The MAH submission should be organised around the referral questions.

A useful structure is:

  1. executive summary;
  2. regulatory history;
  3. scope of affected products;
  4. evidence review;
  5. scientific analysis;
  6. benefit-risk assessment;
  7. proposed regulatory conclusions;
  8. proposed product-information changes;
  9. supporting appendices.

The submission should make it easy for assessors to locate the evidence supporting each conclusion.

38. The List of Questions

Committees may issue questions where additional clarification or evidence is required.

A controlled response matrix should record:

Question Owner Evidence Draft answer QC status Final response
Q1 Function Source Draft Review Final
Q2 Function Source Draft Review Final

This structure reduces omissions and makes cross-functional review more reliable.

The response should answer the question asked rather than using the question as an opportunity to introduce unrelated arguments.

39. Clock-Stops and Procedural Pauses

Some referral procedures permit periods during which the formal assessment clock is stopped to allow the MAH to provide additional information.

The precise operation of clock-stops depends on the procedure.

Companies should therefore maintain a dated chronology showing:

This prevents internal project dates from being confused with formal regulatory deadlines.

40. Assessment Reports

Assessment reports document the scientific evaluation undertaken by the rapporteur team.

They can identify:

The report should be read as part of the procedural record.

It should not automatically be treated as the final committee position until the relevant committee has formally adopted its conclusion.

41. Outstanding Issues

After reviewing the initial responses, assessors may identify outstanding issues.

An outstanding issue can represent:

The MAH should track each issue separately and ensure that the response addresses the precise residual concern.

42. Oral Explanations

Where the applicable procedure provides for an oral explanation, it should be treated as a formal regulatory interaction.

The presentation should:

The opportunity, timing and format depend on the individual procedure and current guidance.

43. Committee Discussion

The committee evaluates the scientific material collectively.

Discussion can involve:

The committee's conclusion should therefore be understood as the result of the formal assessment process rather than as a direct transcription of one assessor's report.

44. Scientific Consensus and Minority Views

Scientific committees seek a reasoned conclusion based on the available evidence.

Where significant disagreement remains, the regulatory record may document differing scientific positions or the basis on which the committee reached its final conclusion.

For an external reviewer, the important question is not merely whether disagreement existed but whether the final conclusion is supported by the documented evidence and legal framework.

45. PRAC Recommendation

In pharmacovigilance procedures where PRAC is responsible for the safety assessment, PRAC adopts a recommendation according to its applicable legal framework.

The recommendation can address:

The recommendation must then be followed through the subsequent legal procedure where one is required.

46. CHMP Opinion

Where CHMP is required to adopt an opinion, the opinion represents the committee's scientific conclusion under the applicable legislation.

It may contain or refer to:

The opinion should be distinguished from the final legal instrument whenever the procedure requires a subsequent decision by another Union body.

47. Re-Examination

Some referral pathways provide a right for the affected party to request re-examination of a committee conclusion.

Where applicable, the request must comply with the relevant legal and procedural requirements and deadline.

The re-examination should be treated as a defined regulatory process, not as an informal appeal to reopen every aspect of the procedure.

The exact scope and procedure depend on the applicable legal basis.

48. Grounds for Re-Examination

A re-examination request should identify the grounds on which the applicant or MAH considers the conclusion should be reconsidered.

The request should distinguish:

The relevant legislation and procedure determine what grounds and evidence can be considered.

49. Re-Examination Assessment

Where re-examination occurs, the committee follows the applicable procedural safeguards and may appoint assessors according to the relevant rules.

The company should maintain a separate re-examination evidence package and avoid creating inconsistencies with the original submission unless the procedural basis justifies a change.

The final re-examination conclusion should be archived together with the original opinion and supporting documents.

50. Final Scientific Conclusion

Once the applicable committee process is complete, the scientific conclusion should be documented clearly.

The conclusion should answer:

  1. What was the original regulatory question?
  2. What evidence was considered?
  3. What did the committee conclude?
  4. What uncertainty remains?
  5. What regulatory consequence follows?

This creates a traceable bridge from the scientific record to the legal implementation phase.

51. European Commission Decision

Where the applicable procedure requires a Commission decision, the CHMP opinion or other committee conclusion enters the Union decision-making process.

The Commission decision establishes the operative legal outcome according to the applicable legislation.

The company should therefore identify the final decision separately from:

The final decision and its annexes should control implementation.

52. Conditions of Authorisation

A final regulatory outcome can alter the conditions under which a medicinal product is authorised.

Potential consequences include:

The exact obligation must be established from the final regulatory instrument.

53. Product-Information Implementation

Once final wording is established, the MAH should implement the changes across the relevant product-information components.

This can include:

The implementation package should demonstrate that all affected components were updated consistently.

54. National Implementation

For nationally authorised medicines, the final Union outcome may require action in individual Member States.

The implementation plan should identify:

The exact mechanism depends on the referral pathway and final legal instrument.

55. Centrally Authorised Implementation

For centrally authorised medicines, implementation follows the applicable Union authorisation framework.

The MAH should ensure that the centrally authorised product information and associated regulatory systems reflect the final outcome.

The company should also determine whether manufacturing, distribution, safety monitoring or communication activities require corresponding updates.

56. Communication and Risk Minimisation

Where the final outcome changes how a risk is managed, communication measures may form part of implementation.

Potential activities include:

The exact requirement should be taken from the final regulatory decision and current applicable guidance.

57. Pharmacovigilance System Impact

A referral outcome can affect the pharmacovigilance system even when the original referral involved another regulatory dimension.

The MAH should assess whether the outcome changes:

The QPPV should be able to demonstrate that the relevant impact assessment was completed.

58. Quality and Manufacturing Impact

Some referral outcomes can affect quality or manufacturing controls.

Potential changes include:

The relevant quality functions should determine the impact through the established change-control system.

59. Regulatory Change Control

The final outcome should enter the company's formal regulatory change-control process.

A robust change record should connect:

Final regulatory decision
          ↓
Required change
          ↓
Affected systems
          ↓
Responsible owners
          ↓
Implementation evidence
          ↓
Regulatory closure

This provides an auditable bridge between the regulatory procedure and operational compliance.

60. Closing the Referral Internally

A referral should not be considered operationally complete merely because the committee has issued its opinion or the Commission has adopted its decision.

The MAH should confirm that all applicable implementation activities have been completed and documented.

The closure review should cover:

Only then can the organisation demonstrate that the regulatory conclusion has been converted into controlled operational compliance.

61. Why the Final Decision Matters

The regulatory process does not end with publication of a scientific assessment.

For operational purposes, the organisation must identify the final instrument that establishes what the MAH must do.

Depending on the referral route, this may be a Commission decision, a CMDh position or another legally applicable regulatory outcome.

The implementation team should therefore work from the final operative document and its annexes.

62. Translating the Outcome Into Actions

A useful implementation matrix converts each regulatory conclusion into an operational action.

Regulatory conclusion Required action Owner Deadline Evidence
Product information change Update approved text Regulatory Date Approval
Risk-minimisation change Implement measure PV/Medical Date Completion record
Quality change Change control Quality Date Closure
Commitment Submit required evidence Regulatory/PV Date Submission

This prevents a high-level regulatory conclusion from being lost during implementation.

63. Product Information as a Controlled Regulatory Record

The final authorised product information should be treated as a controlled regulatory record.

The MAH should reconcile:

Draft wording, proposed wording and final approved wording should remain distinguishable in the document history.

64. Risk-Minimisation Implementation

When the outcome requires additional risk minimisation, implementation should cover the complete measure rather than merely the wording of the product information.

The organisation may need to control:

The precise obligations depend on the final regulatory outcome and applicable guidance.

65. Regulatory Commitments

Some referral outcomes create continuing commitments.

Each commitment should be recorded with:

  1. the exact regulatory requirement;
  2. responsible function;
  3. accountable individual;
  4. due date;
  5. required deliverable;
  6. submission mechanism;
  7. evidence of completion.

A commitment should remain open until the regulatory evidence demonstrates that it has been fulfilled.

66. Pharmacovigilance Follow-Up

A referral can change the safety context of a medicine even when the immediate regulatory action appears limited.

The MAH should assess whether the outcome requires changes to:

The QPPV should have sufficient visibility to confirm that the pharmacovigilance consequences have been evaluated.

67. Risk Management Plan Changes

Where the final outcome affects identified risks, potential risks or missing information, the RMP should be assessed.

Potential changes can concern:

The current EMA guidance and procedure-specific requirements should determine the appropriate update route.

68. Quality-System Consequences

Regulatory decisions can create quality-system consequences even when the original issue was not a manufacturing problem.

Potential impacts include:

A cross-functional impact assessment should determine which systems require modification.

69. Inspection Readiness

An inspection-ready referral file should allow an inspector to reconstruct the procedure without relying on oral explanations.

The record should demonstrate:

Concern identified
       ↓
Referral initiated
       ↓
Scientific assessment
       ↓
MAH responses
       ↓
Committee conclusion
       ↓
Final regulatory instrument
       ↓
Implementation
       ↓
Closure and ongoing monitoring

Each stage should have dated primary documentation.

70. Regulatory Document Hierarchy

When documents appear to conflict, the regulatory professional should determine which document has legal or procedural precedence.

A practical hierarchy is:

  1. applicable EU legislation;
  2. final binding regulatory decision or applicable CMDh position;
  3. procedure-specific referral documents;
  4. adopted committee opinion or recommendation;
  5. current procedural guidance;
  6. public summaries;
  7. secondary commentary.

The hierarchy can vary according to the precise question and legal route.

71. Why Public Summaries Can Mislead

Public summaries are designed to communicate regulatory outcomes efficiently.

They may not contain the full scientific reasoning, complete product scope or every implementation detail.

They are therefore useful for orientation but should not automatically replace the primary regulatory record when making a live compliance decision.

For material decisions, the underlying legal and procedural documents should be checked.

72. Referral Versus Routine Regulatory Activity

Not every regulatory disagreement is a formal referral.

Routine procedures can include:

A formal referral should be identified from its legal basis and procedure-specific documentation.

73. Referral Versus Safety Signal

A safety signal is a pharmacovigilance concept describing information suggesting a new potentially causal association or a new aspect of a known association that warrants further investigation.

A referral is a formal regulatory procedure.

A signal can contribute to a referral, but the two concepts are not synonymous.

This distinction is particularly important when communicating with non-pharmacovigilance colleagues.

74. Referral Versus Recall

A referral does not automatically mean that a product is being recalled.

A referral may result in:

A recall is a separate operational action governed by its own legal and quality framework.

75. Referral Versus Withdrawal

Withdrawal of a marketing authorisation can be a regulatory consequence in some circumstances, but it should not be inferred merely from the existence of a referral.

The operative outcome must be established from the final regulatory instrument.

External communications should therefore avoid describing a referral as a withdrawal unless the formal regulatory outcome supports that statement.

76. Handling Uncertainty

Regulatory assessments frequently contain uncertainty.

A robust analysis should distinguish:

Uncertainty should not be hidden merely because a decisive regulatory conclusion is required.

A regulator can reach a regulatory conclusion while explicitly recognising residual scientific uncertainty.

77. Evidence Traceability

Every material conclusion in a referral response should be traceable to evidence.

A useful internal structure is:

Regulatory question
      ↓
Claim
      ↓
Evidence source
      ↓
Analysis
      ↓
Scientific conclusion
      ↓
Regulatory consequence

This approach improves both submission quality and inspection readiness.

78. Managing Conflicting Evidence

Conflicting evidence should be described rather than selectively omitted.

The assessment should consider:

The strongest conclusion is not necessarily the conclusion supported by the largest dataset; evidence quality and relevance also matter.

79. Avoiding Post-Hoc Reasoning

The fact that regulators ultimately reached a particular conclusion does not mean that all earlier evidence necessarily pointed unambiguously toward that conclusion.

A defensible regulatory history should preserve the uncertainty and competing interpretations that existed at the time of assessment.

This is particularly important for inspection readiness and future regulatory-intelligence analysis.

80. Regulatory Governance

A mature referral-management process should have clear governance.

At minimum, the organisation should define:

Governance should be proportionate to the potential regulatory and patient impact.

81. Cross-Functional Review

Cross-functional review is valuable because referral consequences often cross organisational boundaries.

A single product-information change can affect:

The regulatory team should retain control of the final regulatory interpretation while ensuring that operational owners understand their obligations.

82. Common Error: Treating All Referrals as the Same

The term “EMA referral” describes a family of formal procedures rather than one universal workflow.

Article 20, Article 30, Article 31 and urgent pharmacovigilance procedures have different legal bases, triggers and committee roles.

The first question in any referral review should therefore be:

Which legal procedure is this?

Only after that should the reviewer apply the relevant procedural framework.

83. Common Error: Starting With the Committee Name

Knowing that PRAC or CHMP is involved does not by itself identify the legal basis.

The same committee can participate in different procedural contexts.

The correct sequence is:

Legal basis
   ↓
Trigger
   ↓
Product authorisation status
   ↓
Procedure
   ↓
Committee role

This prevents procedural concepts from being inferred from committee membership alone.

84. Common Error: Treating the EMA Website as the Complete File

The EMA website is an essential regulatory information source, but the public web record is not necessarily identical to the complete internal regulatory file.

A company should retain its own controlled record of submissions, responses, assessments, decisions and implementation evidence.

Public information should supplement, not replace, the company's regulatory archive.

85. Practical EMA Referral Checklist

Before closing a referral review, confirm:

  1. legal basis identified;
  2. referral type confirmed;
  3. products and authorisations mapped;
  4. formal scope confirmed;
  5. initiating document archived;
  6. regulatory timetable captured;
  7. rapporteurs and committee identified;
  8. MAH submissions archived;
  9. questions and responses reconciled;
  10. scientific assessment reviewed;
  11. final opinion or recommendation identified;
  12. re-examination assessed where applicable;
  13. final legal instrument identified;
  14. product-information consequences implemented;
  15. PV/RMP consequences assessed;
  16. quality consequences assessed;
  17. commitments tracked;
  18. implementation evidence archived;
  19. closure approved;
  20. ongoing obligations transferred to lifecycle systems.

86. Final Perspective: What an EMA Referral Really Is

An EMA referral is best understood as a formal regulatory mechanism for resolving a defined Union-level question concerning one or more medicinal products.

The central principle is that the referral procedure, not the label “EMA referral,” determines the legal and scientific pathway.

A reliable assessment therefore begins with the legal basis and product authorisation status, establishes the precise referral scope and question, follows the evidence through the appropriate scientific committee, distinguishes recommendations and opinions from legally operative decisions, and ends with documented implementation.

The practical lifecycle is:

Regulatory concern
       ↓
Legal trigger
       ↓
Formal referral
       ↓
Defined scope and questions
       ↓
Scientific assessment
       ↓
Committee conclusion
       ↓
Legal decision, where applicable
       ↓
Implementation
       ↓
Lifecycle monitoring

For regulatory, pharmacovigilance and quality professionals, this framework provides a durable way to interpret referral procedures without confusing safety signals, scientific opinions, regulatory decisions and operational actions.

References

  1. European Parliament and Council. Directive 2001/83/EC on the Community code relating to medicinal products for human use, as amended. In particular Articles 30–34, 107i and related provisions governing referral procedures and pharmacovigilance.
  2. European Parliament and Council. Regulation (EC) No 726/2004, as amended, laying down Union procedures for the authorisation, supervision and pharmacovigilance of medicinal products for human and veterinary use and establishing the European Medicines Agency.
  3. European Medicines Agency. Referral procedures for human medicines. Current EMA overview of referral mechanisms, legal bases and procedural pathways.
  4. European Medicines Agency. Questions and answers on Article 20 referrals. Current procedural information for safety-related referrals concerning centrally authorised medicines.
  5. European Medicines Agency. Questions and answers on Article 30 referrals. Current procedural information concerning referrals involving divergent national decisions and harmonisation questions.
  6. European Medicines Agency. Questions and answers on Article 31 pharmacovigilance referrals. Current procedural information concerning Union-interest referrals initiated following evaluation of pharmacovigilance data.
  7. European Medicines Agency. Questions and answers on Article 31 non-pharmacovigilance referrals. Current procedural information concerning quality, efficacy and other non-pharmacovigilance referral questions.
  8. European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC). Current information on PRAC responsibilities and pharmacovigilance scientific assessment.
  9. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Current information on CHMP responsibilities and scientific assessment.
  10. European Medicines Agency. Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh). Current information on coordination of nationally authorised medicines and MRP/DCP procedures.
  11. European Medicines Agency. Guide to information on human medicines evaluated by EMA — What EMA publishes and when. Current information concerning publication of referral documents, assessment reports, opinions and related regulatory material.
  12. European Commission. Notice to Applicants, Volume 2A — Procedures for marketing authorisation, Chapter 3: Union Referral Procedures. Current version should be consulted for procedural requirements.
  13. European Commission. Notice to Applicants, Volume 2A — Decision-making procedure for the adoption of Commission Decisions. Current version should be consulted where a referral proceeds to a Commission decision.
  14. European Medicines Agency. Current Good Pharmacovigilance Practices (GVP) guidance, particularly modules relevant to signal management, risk management and pharmacovigilance systems.
  15. European Medicines Agency. Current product-information and risk-management guidance, where relevant to implementation of referral outcomes.

Primary-document hierarchy

For a live regulatory assessment, primary documents should take precedence over general explanatory material. A practical hierarchy is:

  1. applicable EU legislation;
  2. formal referral notification and procedure-specific documents;
  3. final Commission decision or applicable CMDh position;
  4. final CHMP opinion and PRAC recommendation, as applicable;
  5. procedure-specific assessment reports and annexes;
  6. current EMA, CMDh and European Commission procedural guidance;
  7. public summaries and secondary explanations.

The correct document depends on the question being answered. Scientific reasoning may require an assessment report, whereas an operative legal requirement may be established by a final decision and its annexes.

Regulatory Note

This article is an educational and regulatory-reference document explaining the EU referral system for medicinal products for human use. It is not legal advice and should not be used as a substitute for applicable legislation, current regulatory guidance or procedure-specific documents.

EU medicines legislation, EMA procedures, CMDh processes and publication practices can change. The applicable consolidated legislation and current official regulatory documents should therefore be checked whenever a live referral is being assessed.

The article deliberately distinguishes general procedural principles from case-specific facts. The precise legal basis, scope, timetable, committee responsibilities, questions, evidence, scientific conclusions, re-examination rights, final decision and implementation requirements must be established from the documents governing the individual procedure.

Do not infer a final legal outcome solely from an EMA webpage summary, committee meeting highlight, preliminary assessment or secondary source. Where applicable, the final Commission decision, CMDh position, CHMP opinion, PRAC recommendation and their annexes should be reviewed according to the relevant legal pathway.

Where an individual referral is underway, the procedure-specific timetable, formal regulatory communications, primary documents, final legal instrument and applicable EU legislation take precedence over the generic descriptions in this article.

Nothing in this article should be interpreted as creating a regulatory obligation that is not contained in applicable EU legislation, a binding regulatory decision or another applicable regulatory requirement.

Revision History

Related Articles

EMA Referral Types Explained: Article 20, Article 31, Article 107i and Article 30

A textbook guide to distinguishing Article 20, Article 31, Article 107i and Article 30 referrals in EU medicines regulation, with particular attention to pharmacovigilance, Union interest, urgency, harmonisation and the roles of PRAC, CHMP and CMDh.

Article 107i Urgent Union Procedures: How Urgent Safety Action Works

How urgent Union pharmacovigilance procedures are initiated, assessed by PRAC and carried through CHMP or CMDh, including the distinction between urgent safety action and ordinary referral procedures.

How an EMA Safety Referral Starts: From Safety Concern to Formal EU Procedure

A textbook explanation of how a safety concern moves from routine pharmacovigilance and regulatory assessment into a formal EU referral, and how the legal basis, urgency, product scope and initiating authority determine the procedure.

Last reviewed: 2026-08-23